[Cervical dilatation by use of a vaginal suppository of meteneprost before voluntary interruption of the pregnancy in the first trimester].
Instrumental dilatation of the cervix prior to first trimester absorption may be difficult and source of complications. Pharmacological dilatation is proposed in a prospective random study using vaginal suppository containing 10 mg of 9-deoxo, 16-16 dimethyl, 9 methylene PGE2 (Meteneprost). Mean cervical dilatation, 3 hours after treatment, was significantly higher in the treated group (8.1 vs 6 mm) and additional dilatation was facilitated by cervical softening. Side effects occurred in most of the treated patients (uterine pain) but on a minor scale. This procedure may be considered as effective, safe and easy.
Maria
B
B
Service de Gynécologie-Obstétrique, Centre Hospitalier, Villeneuve-Saint-Georges.
André-David
F
F
Oury
J F
JF
Stampf
F
F
Bresson
E
E
Rosenberg
P
P
D015064:16,16-Dimethylprostaglandin E2 / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000019:Abortifacient Agents / Q000627:therapeutic use*; D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D000032:Abortion, Therapeutic; D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*; D011897:Random Allocation; D014619:Vacuum Curettage
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D011459:Prostaglandins E, Synthetic; C025505:meteneprost; D015064:16,16-Dimethylprostaglandin E2
Dilatation cervicale par ovule vaginal de Méténéprost avant les IVG du premier trimestre.